Management costs and economic burden of haemophilia  A high in France
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news

UniQure stock falls after news of new CFO, acquisition, and new trial data
Shares of UniQure N.V., a Netherlands-based biotech with U.S. headquarters in Lexington, fell on Tuesday after three very different announcements involving a new top executive, an acquisition and new trial data. UniQure (Nasdaq: QURE) share prices were hovering around $30 as of 2:45 p.m., a decrease of more than 8%, giving the company a market cap of $1.4 billion. The company earlier in the day announced positive topline data from a Phase 3 study of its hemophilia B drug, etranacogene dezaparvovec,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 22, 2021 Category: American Health Authors: Rowan Walrath Source Type: news

Up close and personal – The Dr. Kevin Williams story
From a young age, Dr. Kevin Williams looked to his father as a role model. Back in 1952, his father became the third African American physician in Baton Rouge, Louisiana, despite barriers and discrimination faced by Black professionals in the medical field.   “It was a different time,” says Kevin. “When my father first opened his practice, none of the hospitals would give him admitting privileges.”  At his office, Kevin ’s father saw patients on a first come, first served basis. Patients in the area were so eager to see him that they started lining up at 4 o’clock each morning, even creating their own sign-...
Source: EyeForPharma - June 7, 2021 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Up close and personal – The Dr. Kevin Williams story
From a young age, Dr. Kevin Williams looked to his father as a role model. Back in 1952, his father became the third African American physician in Baton Rouge, Louisiana, despite barriers and discrimination faced by Black professionals in the medical field.   “It was a different time,” says Kevin. “When my father first opened his practice, none of the hospitals would give him admitting privileges.”  At his office, Kevin ’s father saw patients on a first come, first served basis. Patients in the area were so eager to see him that they started lining up at 4 o’clock each morning, even creating their own sign-...
Source: EyeForPharma - June 7, 2021 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news

Health Costs Over 25 Times Higher for Patients With Hemophilia B Health Costs Over 25 Times Higher for Patients With Hemophilia B
As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Namibia: Mother and Sons' Journey With Haemophilia
[Namibian] Joys of a mother come from seeing her sons growing into men, with the bruises and all that come from engaging other boys of their age, but this was not the case with Veronica Mayiji. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 21, 2021 Category: African Health Source Type: news

B cell activating factor possible key to hemophilia immune tolerance
(Indiana University School of Medicine) A group of scientists have just made a key discovery that could prevent and eradicate immune responses that lead to treatment failure in about one-third of people with severe hemophilia A. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 19, 2021 Category: International Medicine & Public Health Source Type: news

CHOP-led research study identifies key target in treatment-resistant hemophilia A
(Children's Hospital of Philadelphia) Researchers at Children's Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2021 Category: International Medicine & Public Health Source Type: news

BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
RMAT Designation Granted by FDA During Bleeding Disorders Awareness Month SAN RAFAEL, Calif., March 8, 2021 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administrat... Biopharmaceuticals, FDA BioMarin, Valoctocogene Roxaparvovec, Hemophilia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 8, 2021 Category: Pharmaceuticals Source Type: news

Fidelis Specialty Pharmacy Selects Citus Health to Enable Real-Time...
Innovative specialty pharmacy provider for hemophiliac and bleeding disorder patients to implement Citus Health’s HIPAA-compliant digital health solution suite to improve patient and staff...(PRWeb March 04, 2021)Read the full story at https://www.prweb.com/releases/fidelis_specialty_pharmacy_selects_citus_health_to_enable_real_time_virtual_patient_communications_and_faster_collection_of_key_patient_data/prweb17770242.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 4, 2021 Category: Pharmaceuticals Source Type: news

Mission 2030: Bayer ’s quest for climate neutrality
One hundred times per week. That ’s how often specially trained Bayer team members used to clean certain stainless-steel vessels as part of a six-month-long drug manufacturing process. The medicine in question is a biotech treatment for people with a rare blood-clotting disorder. The vessels held buffering agents, solutions that are used in the purification process of making Factor VIII, the protein missing in people living with hemophilia A. Cleaning each vessel required significant amounts of… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 26, 2021 Category: Health Management Authors: Lauren Lawley Head Source Type: news

Sudden death of a young hemophiliac by low-velocity blunt knee trauma in bullock cart run-over fatality - Chauhan M, Behera C, Rustagi A.
A young bullock cart driver was pushing bulls hard in stunt and frolic. The cart sped up and he lost control and toppled in front of the iron wheel, which ran over his lower limb around the knee. Concomitant hemophilia further complicated the popliteal art... (Source: SafetyLit)
Source: SafetyLit - February 17, 2021 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Roche reports solid results in 2020
Commenting on the Group ’s results, Roche CEO Severin Schwan said: “Roche continues to make important contributions to fighting the COVID-19 pandemic. We developed in record time a comprehensive portfolio of diagnostic solutions and entered new partnerships to develop and produce effective COVID-19 medicines. The deman d for our new medicines which benefit people living with serious conditions, such as cancer, multiple sclerosis, haemophilia and spinal muscular atrophy, remains high. Based on our rejuvenated portfolio and the significant progress made in developing our product pipeline, Roche is strongly positione d fo...
Source: Roche Investor Update - February 4, 2021 Category: Pharmaceuticals Source Type: news

Roche reports solid results in 2020
Commenting on the Group ’s results, Roche CEO Severin Schwan said: “Roche continues to make important contributions to fighting the COVID-19 pandemic. We developed in record time a comprehensive portfolio of diagnostic solutions and entered new partnerships to develop and produce effective COVID-19 medicines. The deman d for our new medicines which benefit people living with serious conditions, such as cancer, multiple sclerosis, haemophilia and spinal muscular atrophy, remains high. Based on our rejuvenated portfolio and the significant progress made in developing our product pipeline, Roche is strongly positione d fo...
Source: Roche Media News - February 4, 2021 Category: Pharmaceuticals Source Type: news

New follow-up phase III data reinforce the long-term benefit of Roche ’s Hemlibra for people with haemophilia A
Basel, 7 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from a new analysis of pooled, three-year follow-up data of 401 people with haemophilia A from the pivotal HAVEN 1-4 studies, which reinforce the long-term efficacy and safety profile of Hemlibra ® (emicizumab).[1]These data, from adults, adolescents and children with haemophilia A with and without factor VIII inhibitors, were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 5-8 December 2020.“The long-term benefit of Hemlibra, with a consistent safety profile and durably effective con...
Source: Roche Investor Update - December 7, 2020 Category: Pharmaceuticals Source Type: news